On September 19, ISPIRE (ISPR.US), a tech company known as "Fog Hemp Technology," released its fiscal year 2023 report. The performance report reveals that ISPIRE experienced a revenue growth of 31.2% in the 2023 fiscal year, reaching a total of $115.6 million.
Michael Wang, Co-CEO of ISPIRE, has described the 2023 fiscal year as a significant milestone for the company. Revenue from CBD and e-cigarette products saw impressive growth of 100.4% and 10.9% respectively, contributing to an overall revenue increase of 31.2%. This growth was primarily driven by a doubling of income from ISPIRE's CBD vaporizer products in the United States and increased sales of e-cigarette products in Europe.
He stated that the key to this success is ISPIRE's multi-pronged strategy: expanding the sales of CBD vaporizer products to provide innovative solutions for both medical and recreational sectors.
He also stated that ISPIRE's factory in California, United States, will launch its first fully automated assembly line by the end of 2023. Furthermore, ISPIRE is actively considering Southeast Asia as a potential manufacturing hub for future business, aiming to further optimize production capacity.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
